Who Generates More Revenue? Amgen Inc. or Novavax, Inc.

Revenue Showdown: Amgen Inc. vs. Novavax, Inc.

In the ever-evolving landscape of biotechnology, revenue generation is a key indicator of a company's market position and growth potential. Over the past decade, Amgen Inc. has consistently outperformed Novavax, Inc. in terms of revenue. From 2014 to 2023, Amgen's revenue has grown by approximately 40%, reaching its peak in 2023. In contrast, Novavax, despite its significant contributions to vaccine development, particularly during the COVID-19 pandemic, has seen a more volatile revenue trajectory. Notably, Novavax's revenue surged in 2021 and 2022, reflecting a 3000% increase from its 2014 figures, but it still remains a fraction of Amgen's earnings. This comparison highlights the stability and dominance of Amgen in the biotech sector, while Novavax's revenue spikes underscore its potential for rapid growth in response to global health needs.